Trials / Terminated
TerminatedNCT03436771
Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product
Long-Term Follow-up Protocol for Subjects Treated With a CAR T-Cell Product on a Juno-Sponsored Clinical Trial
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 4 (actual)
- Sponsor
- Juno Therapeutics, a Subsidiary of Celgene · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.
Conditions
- Non Hodgkin Lymphoma
- Multiple Myeloma
- Chronic Lymphocytic Leukemia
- Diffuse Large B Cell Lymphoma
- Mantle Cell Lymphoma
- Follicular Lymphoma
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | JCAR017 | No drug is administered in this study. Patients who received JCAR017 in a previous trial will be evaluated in this trial for long-term safety and survival. |
| GENETIC | JCARH125 | No drug is administered in this study. Patients who received JCARH125 in a previous trial will be evaluated in this trial for long-term safety and survival. |
Timeline
- Start date
- 2018-02-19
- Primary completion
- 2018-07-20
- Completion
- 2018-07-20
- First posted
- 2018-02-19
- Last updated
- 2020-05-04
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03436771. Inclusion in this directory is not an endorsement.